Antifungal susceptibility of invasive yeast isolates in Italy: the GISIA3 study in critically ill patients

[1]  C. Bonnal,et al.  Comparison of antifungal MICs for yeasts obtained using the EUCAST method in a reference laboratory and the Etest in nine different hospital laboratories. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  J. Pemán,et al.  Comparison of Anidulafungin MICs Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Method (M27-A3 Document) and Etest for Candida Species Isolates , 2009, Antimicrobial Agents and Chemotherapy.

[3]  M. Pfaller,et al.  In Vitro Activity of Seven Systemically Active Antifungal Agents against a Large Global Collection of Rare Candida Species as Determined by CLSI Broth Microdilution Methods , 2009, Journal of Clinical Microbiology.

[4]  J. Pemán,et al.  Comparison of 24-Hour and 48-Hour Voriconazole MICs as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Method (M27-A3 Document) in Three Laboratories: Results Obtained with 2,162 Clinical Isolates of Candida spp. and Other Yeasts , 2009, Journal of Clinical Microbiology.

[5]  E. Anaissie,et al.  Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  J. Sobel,et al.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  E. Bouza,et al.  Epidemiology of candidemia in intensive care units. , 2008, International journal of antimicrobial agents.

[8]  E. Mellado,et al.  Clinical relevance of resistance to antifungals. , 2008, International journal of antimicrobial agents.

[9]  M. Deplano,et al.  Prevalence of Candida species in different hospital wards and their susceptibility to antifungal agents: results of a three year survey. , 2008, Journal of preventive medicine and hygiene.

[10]  G. Fadda,et al.  The ATP‐binding cassette transporter–encoding gene CgSNQ2 is contributing to the CgPDR1‐dependent azole resistance of Candida glabrata , 2008, Molecular microbiology.

[11]  M. Montagna,et al.  Observational study on candidaemia at a university hospital in southern Italy from 1998 to 2004 , 2008, Mycoses.

[12]  S. Oliveri,et al.  In Vitro Activity of Fluconazole, Voriconazole and Caspofungin against Clinical Yeast Isolates , 2007, Journal of chemotherapy.

[13]  M. Pfaller,et al.  In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance , 2006, Journal of Clinical Microbiology.

[14]  M. Bassetti,et al.  Epidemiological trends in nosocomial candidemia in intensive care , 2006, BMC infectious diseases.

[15]  A. Tortorano,et al.  The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isolates and biofilm production. , 2005, The Journal of antimicrobial chemotherapy.

[16]  Victoria J. Fraser,et al.  Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality , 2005, Antimicrobial Agents and Chemotherapy.

[17]  L. Polonelli,et al.  Voriconazole activity against clinical yeast isolates: a multicentre Italian study. , 2005, International journal of antimicrobial agents.

[18]  M. Pfaller,et al.  Comparison of Visual 24-Hour and Spectrophotometric 48-Hour MICs to CLSI Reference Microdilution MICs of Fluconazole, Itraconazole, Posaconazole, and Voriconazole for Candida spp.: a Collaborative Study , 2005, Journal of Clinical Microbiology.

[19]  E. Mellado,et al.  Correlation between the procedure for antifungal susceptibility testing for Candida spp. of the European Committee on Antibiotic Susceptibility Testing (EUCAST) and four commercial techniques. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[20]  O. Faure,et al.  Epidemiology of Candidaemia in Europe: Results of 28-Month European Confederation of Medical Mycology (ECMM) Hospital-Based Surveillance Study , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[21]  C. M. Belli,et al.  Multicenter Comparative Evaluation of Six Commercial Systems and the National Committee for Clinical Laboratory Standards M27-A Broth Microdilution Method for Fluconazole Susceptibility Testing of Candida Species , 2002, Journal of Clinical Microbiology.

[22]  M. Pfaller,et al.  Epidemiology of Candidemia: 3-Year Results from the Emerging Infections and the Epidemiology of Iowa Organisms Study , 2002, Journal of Clinical Microbiology.

[23]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[24]  Ellen Jo Baron,et al.  Manual of clinical microbiology , 1975 .

[25]  Steven D. Brown,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Third informational supplement , 2008 .

[26]  C. Mussini,et al.  Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[27]  Patrick R. Murray,et al.  Candida, Cryptococcus, and other yeasts of medical importance. , 2006 .